Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy.

Barygina VV, Becatti M, Soldi G, Prignano F, Lotti T, Nassi P, Wright D, Taddei N, Fiorillo C.

Redox Rep. 2013;18(3):100-6. doi: 10.1179/1351000213Y.0000000045. Epub 2013 Apr 19.

PMID:
23601139
2.

Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.

Markham T, Mullan R, Golden-Mason L, Rogers S, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ.

J Am Acad Dermatol. 2006 Jun;54(6):1003-12. Epub 2006 Mar 20.

PMID:
16713454
3.

Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment.

Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, Esposito M, Tiberti S, Chimenti S, DE Lorenzo A.

Dermatol Ther. 2011 Jul-Aug;24(4):446-51. doi: 10.1111/j.1529-8019.2011.01439.x.

PMID:
21910803
4.

Clastogenic plasma factors in psoriasis--comparison of phototherapy and anti-TNF-α treatments.

Emerit I, Antunes J, Silva JM, Freitas J, Pinheiro T, Filipe P.

Photochem Photobiol. 2011 Nov-Dec;87(6):1427-32. doi: 10.1111/j.1751-1097.2011.00982.x. Epub 2011 Sep 14.

PMID:
21824151
5.
6.

Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review.

Chimenti MS, Spinelli FR, Giunta A, Martinelli F, Saraceno R, Conti F, Perricone R, Valesini G.

Drug Dev Res. 2014 Nov;75 Suppl 1:S61-3. doi: 10.1002/ddr.21198.

PMID:
25381980
7.

High density cholesterol level as predictor of clinical response to anti-TNF-alpha therapy in psoriatic patients.

Saraceno R, Rizza S, Faleri S, Federici M, Nistico SP, Copetti M, Chimenti S.

J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):903-8.

PMID:
24152855
8.

Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment.

Bacchetti T, Campanati A, Ferretti G, Simonetti O, Liberati G, Offidani AM.

Br J Dermatol. 2013 May;168(5):984-9. doi: 10.1111/bjd.12144.

PMID:
23614561
9.

Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment.

Prignano F, Pescitelli L, Ricceri F, Ermini A, Lotti T.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1444-8. doi: 10.1111/j.1468-3083.2011.04216.x. Epub 2011 Aug 11.

PMID:
21834947
10.

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

Tobin AM, Kirby B.

BioDrugs. 2005;19(1):47-57. Review.

PMID:
15691217
11.

Modification of osteopontin and MMP-9 levels in patients with psoriasis on anti-TNF-α therapy.

Buommino E, De Filippis A, Gaudiello F, Balato A, Balato N, Tufano MA, Ayala F.

Arch Dermatol Res. 2012 Aug;304(6):481-5. doi: 10.1007/s00403-012-1251-3. Epub 2012 Jun 9.

PMID:
22684781
12.
13.

Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.

Gisondi P, Cotena C, Tessari G, Girolomoni G.

J Eur Acad Dermatol Venereol. 2008 Mar;22(3):341-4. Epub 2007 Nov 14.

PMID:
18005022
14.

Alterations of redox-status during psoriasis.

Matoshvili M, Katsitadze A, Sanikidze T, Tophuria D, Richetta A, D'Epiro S.

Georgian Med News. 2014 Jul-Aug;(232-233):60-4.

PMID:
25214274
15.

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.

Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T, Node K.

Atherosclerosis. 2012 Apr;221(2):375-82. doi: 10.1016/j.atherosclerosis.2011.12.039. Epub 2012 Jan 4.

PMID:
22284365
16.

Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.

Channual J, Wu JJ, Dann FJ.

Dermatol Ther. 2009 Jan-Feb;22(1):61-73. doi: 10.1111/j.1529-8019.2008.01217.x. Review.

PMID:
19222518
17.

Glutathione peroxidase activity in the blood cells of psoriatic patients correlates with their responsiveness to Efalizumab.

Pastore S, Mariani V, Lulli D, Gubinelli E, Raskovic D, Mariani S, Stancato A, de Luca C, Pecorelli A, Valacchi G, Potapovich AI, Kostyuk VA, Korkina LG.

Free Radic Res. 2011 May;45(5):585-99. doi: 10.3109/10715762.2011.560150. Epub 2011 Feb 16.

PMID:
21323509
18.

Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?

Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR.

J Clin Rheumatol. 2008 Dec;14(6):353-6. doi: 10.1097/RHU.0b013e318190dd88.

PMID:
19033869
19.

Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers.

Gubandru M, Margina D, Tsitsimpikou C, Goutzourelas N, Tsarouhas K, Ilie M, Tsatsakis AM, Kouretas D.

Food Chem Toxicol. 2013 Nov;61:209-14. doi: 10.1016/j.fct.2013.07.013. Epub 2013 Jul 16.

PMID:
23871825
20.

The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis.

Karkucak M, Capkin E, Alver A, Akyuz A, Kiris A, Ak E, Topbas M, Tosun M.

Clin Rheumatol. 2010 Mar;29(3):303-7. doi: 10.1007/s10067-009-1325-6. Epub 2009 Dec 11.

PMID:
20012550

Supplemental Content

Support Center